Low-calcemic oxime analogs of 1α,25-dihydroxy vitamin D3
US6982258B2 · kind B2 · utility
47Cited by
1References
42Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Oct 15, 2002 |
| Grant date | Jan 3, 2006 |
| Priority date | — |
| Expiry date | Feb 13, 2023 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides novel 16-ene-C25-oxime and 16-ene-C-25-oxime ether analogs of 1α,25-dihydroxy vitamin D3, compositions comprising these compounds and methods of using these compounds as inhibitors of CYP24. In particular, the compound of Formula I are useful for treating diseases which benefit from a modulation of the levels of 1α,25-dihydroxy vitamin D3, for example, cell-proliferative disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.